Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

27.01 +0.53 (+2.00%)
Streaming Delayed Price Updated: 11:44 AM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 347,252
Open 26.32
Bid (Size) 26.99 (200)
Ask (Size) 27.08 (100)
Prev. Close 26.48
Today's Range 25.86 - 27.06
52wk Range 13.53 - 35.25
Shares Outstanding 79,199,501
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics (BEAM) Earnings Transcript ↗
Beam Therapeutics (BEAM) Earnings Transcript 
Via The Motley Fool
Topics Death

Performance

YTD
+9.4%
+9.4%
1 Month
+24.8%
+24.8%
3 Month
+32.6%
+32.6%
6 Month
+49.4%
+49.4%
1 Year
-1.8%
-1.8%

More News

Read More
News headline image
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
Is Beam Therapeutics Gaining or Losing Market Support? ↗
Via Benzinga
News headline image
What Does the Market Think About Beam Therapeutics? ↗
Via Benzinga
News headline image
AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
Via TokenRing AI
Topics Artificial Intelligence Climate Change Intellectual Property
News headline image
Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys ↗
Via Benzinga
News headline image
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
News headline image
WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday ↗
Via Benzinga
Topics Artificial Intelligence
News headline image
Jefferies Initiates Beam Therapeutics with "Buy" Rating, Eyeing Promising Gene-Editing Pipeline and Upcoming Catalysts
Via MarketMinute
News headline image
Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves ↗
Via Benzinga
Topics Artificial Intelligence
News headline image
Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors
Via MarketMinute
Topics Artificial Intelligence Climate Change Economy
News headline image
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗
Via Benzinga
News headline image
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
News headline image
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
News headline image
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease ↗
Via Benzinga
News headline image
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
News headline image
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Cathie Wood's Ark Invest Continues To Offload Coinbase, Bets Big On SoFi Technologies ↗
Via Benzinga
News headline image
The FDA Shake-Up Continues, And Could Impact Genetic Medicines ↗
Via Investor's Business Daily
Topics Government
News headline image
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗
Via Benzinga
News headline image
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover ↗
Via Investor's Business Daily
News headline image
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
From Beam Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Beam Therapeutics Inc. - Common Stock publicly traded?
Yes, Beam Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Beam Therapeutics Inc. - Common Stock trade on?
Beam Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Beam Therapeutics Inc. - Common Stock?
The ticker symbol for Beam Therapeutics Inc. - Common Stock is BEAM on the Nasdaq Stock Market
What is the current price of Beam Therapeutics Inc. - Common Stock?
The current price of Beam Therapeutics Inc. - Common Stock is 27.01
When was Beam Therapeutics Inc. - Common Stock last traded?
The last trade of Beam Therapeutics Inc. - Common Stock was at 12/10/25 11:44 AM ET
What is the market capitalization of Beam Therapeutics Inc. - Common Stock?
The market capitalization of Beam Therapeutics Inc. - Common Stock is 2.14B
How many shares of Beam Therapeutics Inc. - Common Stock are outstanding?
Beam Therapeutics Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.